FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment
April 6, 2018 8:05 pmThe Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more